CN1729989A - Medicine composition for treating cardiovascular and cerebrovascular disease and its preparation method - Google Patents
Medicine composition for treating cardiovascular and cerebrovascular disease and its preparation method Download PDFInfo
- Publication number
- CN1729989A CN1729989A CN 200410078812 CN200410078812A CN1729989A CN 1729989 A CN1729989 A CN 1729989A CN 200410078812 CN200410078812 CN 200410078812 CN 200410078812 A CN200410078812 A CN 200410078812A CN 1729989 A CN1729989 A CN 1729989A
- Authority
- CN
- China
- Prior art keywords
- troxerutin
- breviscapine
- pharmaceutical composition
- weight portion
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a medicinal composition for treating cardiovascular and cerebrovascular diseases and its preparing process, more specifically a medicinal composition containing Troxerutin and Breviscapine and the preparing process. The composition has the function of activating blood circulation, stasis removing and vein relaxing.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease and preparation method thereof, particularly relate to a kind of with combined pharmaceutical composition of troxerutin and breviscapine and preparation method thereof.
Background technology
Apoplexy is old people's commonly encountered diseases, frequently-occurring disease, be one of old people's three big causes of the death, in recent years, the whole nation, whole world sickness rate have the trend of increasing, cardiovascular and cerebrovascular disease has risen to cause of death first place, annual nearly 540,000 people in the whole nation suffer from the apoplexy disease, after acute stage, often leave over many sequela, as hemiplegia, dementia, aphasia or the like, patient and family and society are caused great misery and burden, two sequela of leaving over, annual treatment 3～6 months that approximately need.Apoplexy can not be greatly two classes, i.e. cerebral infarction and hemorrhagic apoplexy, and wherein cerebral infarction accounts for 80 percent, therefore.Develop the medicine of effectively preventing ischemic apoplexy sequelae, have home and overseas market and high economic benefit and social benefit preferably.
Angina pectoris is familiar with by extensive patients as common type of coronary heart disease.Its basic pathology basis is luminal stenosis and coronary vasospasm and the myocardial ischemia that causes due to the coronary atherosclerosis.Angina pectoris is a coronary insufficiency, and cardiac muscle is the clinical symptoms due to the ischemia sharply, and along with the further investigation to coronary heart disease, the angina pectoris typing is clearer and more definite, and provides theoretical foundation for clinical treatment.
1. stablize labour's angina pectoris: the angina pectoris that takes place behind promptly certain intensity labour.This is because the coronary artery of pathological changes can only satisfy under the rest state or the blood supply of cardiac muscle under the slight exertional state.And labour's intensity increases back myocardial oxygen consumption increase, has produced one and has crossed the property anoxia.The characteristics of this type are to bring out anginal labour's intensity relative fixed, and symptom can be alleviated after the termination activity.Its pathologic basis often since coronarius fixing narrow due to.The course of disease is longer, and the state of an illness is relatively stable.
2. just send out labour's angina pectoris: refer in one month recently the angina pectoris that taken place behind certain intensity labour.Wherein a part can transfer to and stablizes labour's angina pectoris, but also some coronary atherosclerosis progress rapidly, or thrombosis and acute myocardial infarction takes place in the arteria coronaria in a short time.So this type clinical manifestation differs greatly, age of onset is lighter relatively, sees with the male more.
3. worsen labour's angina pectoris: the state of an illness increases the weight of stablizing on labour's angina pectoris basis in a short time, and this kind of angina pectoris takes place.This angina pectoris activity dosis tolerata obviously reduces, even under static state also can show effect, and pain time prolongs, and effect weakens to nitroglycerin.May be because the atherosclerotic plaque inner lipid soaks into to be increased or plaque rupture, local platelet aggregation might develop into acute myocardial infarction.
4. angina pectoris decubitus: outbreak when crouching that its characteristics are flat, because of mostly occurring at night, sitting up during outbreak or standing to make sx.This type patient often has long coronary disease medical history, because of existing myocardiosclerosis and the cardiac insufficiency to a certain degree of secular myocardial ischemia; Or, cardiac load is increased the weight of and angina pectoris takes place because of the flat back returned blood volume that crouches increases.
5. variant angina pectoris: outbreak is many and tired and emotion is irrelevant, often be periodically and show effect morning, and age of onset is lighter.Its maximum characteristics be when outbreak electrocardiogram do not show as that common S-T section moves down, the T ripple is inverted, alarm but show as raising of S-T section with the T wave height, this be since greatly the coronary artery that props up the figure that the wall treating myocardial ischemia damage appears in serious spasm takes place.Its generation is lower with the metabolism in morning, in the blood the few and calcium ion of hydrion too much to enter myocardial cell relevant.Continue serious coronary vasospasm and can cause myocardial infarction or sudden death.Lighter as spasm extent, or side Zhi Xunhuan foundation is better, and electrocardiogram also can show as the S-T section and move down, and is called spontaneous angina pectoris this moment.Increase irrelevant with myocardial oxygen consumption after the activity.
6. mixed type angina pectoris: i.e. labour and spontaneous and deposit.Narrow and the spasm of coronary artery stationarity is also deposited.So angina pectoris can occur in different time, different situations.
At present, though the treatment angina pectoris has had many new techniques, Drug therapy remains important means.Yet rational use of drug but is the key point of angina pectoris control.
The modern medicine clinical research finds that breviscapine has expansion blood capillary, microcirculation improvement, blood viscosity lowering, anticoagulant, promotion fibrinolytic, anti-bolt thrombolytic, increases the perfused tissue amount, eliminates effects such as free radical, blood fat reducing, blood sugar lowering.Troxerutin can suppress hematoblastic gathering, prevents thrombotic effect.In addition the troxerutin blood vessel injury that can also cause medmain, Kallidin I increases capillary resistance, reduces capillary permeability, can prevent the edema that vascular permeability raises and causes, and breviscapine does not have this effect.Troxerutin can be used for hemiplegia, the aphasia due to cerebral thrombosis and the cerebral embolism, arteriosclerosis, central serous chorioretinopathy, thrombophlebitis, varicosis etc. clinically.Both share the enhancing function of promoting blood circulation to disperse blood clots, have increased indication simultaneously.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease and preparation method thereof.
The present invention is achieved through the following technical solutions:
Troxerutin 10-1000 weight portion breviscapine 2-100 weight portion
The optimizing prescriptions amount of pharmaceutical composition of the present invention is:
Troxerutin 100 weight portion breviscapines 20 weight portions
Get troxerutin 1g, breviscapine 0.20g and add injection water 200ml, regulate pH value with 8% sodium hydroxide solution and make its dissolving.Sodium chloride 3.04g, sodium citrate 0.6g are mixed with 10% solution, adding 0.2% active carbon boiled 15 minutes, filter, filtrate adds anhydrous sodium sulfite, EDTA-2Na, troxerutin and breviscapine solution, regulating pH (caustic lye of soda with 8%) is 7.5, and add 0.15% active carbon and boiled 15 minutes, add dimension C dissolving, filter, filtrate adds the injection water to 1000ml, regulate pH (caustic lye of soda) to 7.5 with 8%, medicinal liquid filters 40 bottles of fills, Zha Gai with the microporous filter membrane of 0.45um, 0.22um, in 110 ℃ of pressure sterilizings 40 minutes, promptly.
Troxerutin 10-1000
Breviscapine 2-100 weight portion
The optimizing prescriptions amount of pharmaceutical composition of the present invention is:
Troxerutin 100 weight portions
Breviscapine 20 weight portions
Troxerutin
Assay is measured according to high performance liquid chromatography (2000 editions two appendix VD of Chinese Pharmacopoeia).
Chromatographic condition and system suitability test are filler with octadecylsilane chemically bonded silica; With 0.1% citric acid soln-acetonitrile-oxolane (85: 9: 6) is mobile phase; Detect wavelength 254nm.Number of theoretical plate calculates by the troxerutin peak should be not less than 2000, and the separating degree at troxerutin peak and other material peaks should meet the requirements.
Algoscopy is got this product 2ml, adds mobile phase dissolving and dilution 10ml, and precision is measured 10ul and injected chromatograph of liquid, the record chromatogram; It is an amount of that precision takes by weighing the troxerutin reference substance in addition, measures with method, presses external standard method with calculated by peak area, promptly.
Herba Erigerontis
Assay is measured according to high performance liquid chromatography (2000 editions two appendix VD of Chinese Pharmacopoeia).
Chromatographic condition and system suitability test are filler with octadecylsilane chemically bonded silica; With 0.1% phosphoric acid-methanol-oxolane (68: 16: 16) is mobile phase; Detect wavelength 335nm.
Algoscopy is got this product 2ml, adds mobile phase dissolving and dilution 10ml, and precision is measured 10ul and injected chromatograph of liquid, the record chromatogram; It is an amount of that precision takes by weighing the Herba Erigerontis reference substance in addition, measures with method, presses external standard method with calculated by peak area, promptly
In order to find the best proportioning and the optimal dose of breviscapine (D) and troxerutin (L), we design following 8 compatible combination and screen by two kinds of animal models: 20mg (D): 200mg (L), 20mg (D): 100mg (L), 10mg (D): 200mg (L), 10mg (D): 100mg (L), 40mg (D), 200mg (L), 20mg (D), 100mg (L).
1. the rabbit fibrin lytic activity is measured: 20mg (D): 100mg (L) group can significantly shorten euglobulin lysis time (P＜0.01).All the other each groups all obviously shorten euglobulin lysis time (P＜0.05).
2. the cerebral ischemic model test shows due to the sarsaparilla Mus ligation of carotid method: 100mg (L) group obviously reduces the cerebral cortex water content (P＜0.05) of cerebral ischemia re-pouring pallasiomy, 20mg (D) group effect not obvious (P＞0.05), both share back 20mg (D): 100mg (L) effect and strengthen (P＜0.01).
Both share the enhancing function of promoting blood circulation to disperse blood clots, have increased indication simultaneously.And it is best with 20mg (D): 100mg (L) compound action.
Medicine of the present invention has the activating blood circulation to dissipate blood stasis and dredge the collateral effect through laboratory observation, and experiment shows disease treatments such as can be used for ischemia apoplexy sequela and coronary heart disease.
The test of experimental example 1. dog middle cerebral artery caused by ligature cerebral ischemic models: this pharmaceutical composition of 20mg/kg can reduce the cerebral tissue ischemic region weight after the ligation of dog middle cerebral artery, rising dog middle cerebral artery mean blood flow velocity and peak velocity.
Experimental example 2. rat internal carotid arterys injection thrombosis causes consciousness and motor capacity and the neuroethology symptom that this pharmaceutical composition of local cerebral ischemia model test: 40～20mg/kg can improve focal cerebral ischemia rat 2～24h, and can reduce focal cerebral ischemia rat ischemia district's weight and cerebral ischemia percentage ratio.
Cerebral ischemic model test due to the experimental example 3. sarsaparilla Mus ligation of carotid methods: can the raise LDH vigor of cerebral ischemia re-pouring pallasiomy of this pharmaceutical composition of 40～20mg/kg; reduce the cerebral cortex water content of cerebral ischemia re-pouring pallasiomy; and can alleviate the pallasiomy global brain ischemia and pour into the back Hippocampus neuronic damage in CA1 district again, protect its survival.
Experimental example 4. mice head-breaking global brain ischemia model tests: this pharmaceutical composition of 20～10mg/kg can prolong the number of times of breathing of dehiscing after mice breaks end.
5. pairs of dog cerebral circulation of experimental example blood flow determination: this pharmaceutical composition of 20～5mg/kg does not all have obviously influence to the systolic pressure and the diastolic pressure administration front and back of anesthetized dog.
Experimental example 6. improves the test of cerebral lesion animal pattern learning and memory: this pharmaceutical composition of 40～10mg/kg can reduce by 40% ethanol and cause that mouse memory reproduces the dark experiment errors number of keeping away of obstacle.
Myocardial infarction model test due to the experimental example 7. dog coronary artery ligation methods: this pharmaceutical composition of 20～10mg/kg can make the left ventricle infarction size obviously dwindle, and reduces LDH and the CPK of animal pattern, and the scheming infarction of LAD ligation is had the better protection effect.In addition, this pharmaceutical composition can alleviate after the ligation anterior descending coronary since due to the myocardial ischemia ST section raise, reduce animal heart rate and myocardial oxygen consumption, the LV+dp/dt of elevation model animal, LV-dp/dt.
Downright bad this pharmaceutical composition of model test: 20～5mg/kg of myocardial ischemia can resist the acute myocardial ischemia that pituitrin brings out due to the experimental example 8. medicine methods, and has tangible dose-effect regularity.
Experimental example 9. anti-low sugar hypoxia can reduce LDH, CK and AST to this pharmaceutical composition of protection test of cultivating myocardial cell injury, and In vitro culture myocardial cell anoxia is lacked the sugar damage direct protective effect.
Experimental example 10. dog cardiac functions and this pharmaceutical composition of hemodynamics test 20～5mg/kg can reduce myocardial oxygen consumption, increase coronary flow, the CO of elevation model animal.Hemodynamic parameters such as electrocardio, the average femoral artery pressure of heart rate there is not obvious influence.
Experimental example 11. improves this pharmaceutical composition of mice microcirculation test 40～10mg/kg can both increase the open number of Mice Auricle point of intersect of the capillary network behind the dripping hydrochloric acid epinephrine, and expansion auricle blood capillary is accelerated blood flow rate.
Experimental example 12. improves the rheology test of blood stasis model rat blood: this pharmaceutical composition of 40mg/kg can reduce each index of blood stasis rat model hemorheology, prolongs PT, and good function of promoting blood circulation to disperse blood clots is arranged.
Experimental example 13. strengthens rabbit pulmonary thrombosis solubility tests: this pharmaceutical composition of 40～20mg/kg can reduce the dried wet weight of thrombosis, has good in antithrombotic effect.
Experimental example 14. thrombolytic test-rabbit fibrin lytic activities are measured: fibrin in this pharmaceutical composition energy accelerate dissolution blood plasma of 20～5mg/kg, shorten euglobulin lysis time.
The test of experimental example 15. antiplatelet aggregation: this pharmaceutical composition can reduce platelet aggregation rate.
Description of drawings
Fig. 1 is the high-efficient liquid phase chromatogram of this pharmaceutical composition;
The specific embodiment
Embodiment 1:
Troxerutin 100mg breviscapine 20mg
Get troxerutin 1g, breviscapine 0.20g and add injection water 200ml, regulate pH value with 8% sodium hydroxide solution and make its dissolving.Sodium chloride 3.04g, sodium citrate 0.6g are mixed with 10% solution, adding 0.2% active carbon boiled 15 minutes, filter, filtrate adds anhydrous sodium sulfite, EDTA-2Na, troxerutin and breviscapine solution, regulating pH (caustic lye of soda with 8%) is 7.5, and add 0.15% active carbon and boiled 15 minutes, add dimension C dissolving, filter, filtrate adds the injection water to 1000ml, regulate pH (caustic lye of soda) to 7.5 with 8%, medicinal liquid filters 40 bottles of fills, Zha Gai with the microporous filter membrane of 0.45um, 0.22um, in 110 ℃ of pressure sterilizings 40 minutes, promptly.
Embodiment 2:
Troxerutin 200mg breviscapine 40mg
Get troxerutin 2g, breviscapine 0.40g and add injection water 200ml, regulate pH value with 8% sodium hydroxide solution and make its dissolving.Sodium chloride 3.04g, sodium citrate 0.6g are mixed with 10% solution, adding 0.2% active carbon boiled 15 minutes, filter, filtrate adds anhydrous sodium sulfite, EDTA-2Na, troxerutin and breviscapine solution, regulating pH (caustic lye of soda with 8%) is 7.5, and add 0.15% active carbon and boiled 15 minutes, add dimension C dissolving, filter, filtrate adds the injection water to 1000ml, regulate pH (caustic lye of soda) to 7.5 with 8%, medicinal liquid filters 40 bottles of fills, Zha Gai with the microporous filter membrane of 0.45um, 0.22um, in 110 ℃ of pressure sterilizings 40 minutes, promptly.
Embodiment 3:
Troxerutin 50mg breviscapine 10mg
Get troxerutin 0.5g, breviscapine 0.10g and add injection water 200ml, regulate pH value with 8% sodium hydroxide solution and make its dissolving.Sodium chloride 3.04g, sodium citrate 0.6g are mixed with 10% solution, adding 0.2% active carbon boiled 15 minutes, filter, filtrate adds anhydrous sodium sulfite, EDTA-2Na, troxerutin and breviscapine solution, regulating pH (caustic lye of soda with 8%) is 7.5, and add 0.15% active carbon and boiled 15 minutes, add dimension C dissolving, filter, filtrate adds the injection water to 1000ml, regulate pH (caustic lye of soda) to 7.5 with 8%, medicinal liquid filters 40 bottles of fills, Zha Gai with the microporous filter membrane of 0.45um, 0.22um, in 110 ℃ of pressure sterilizings 40 minutes, promptly.
Embodiment 4:
Troxerutin 100mg breviscapine 10mg
Get troxerutin 1g, breviscapine 0.10g and add injection water 200ml, regulate pH value with 8% sodium hydroxide solution and make its dissolving.Sodium chloride 3.04g, sodium citrate 0.6g are mixed with 10% solution, adding 0.2% active carbon boiled 15 minutes, filter, filtrate adds anhydrous sodium sulfite, EDTA-2Na, troxerutin and breviscapine solution, regulating pH (caustic lye of soda with 8%) is 7.5, and add 0.15% active carbon and boiled 15 minutes, add dimension C dissolving, filter, filtrate adds the injection water to 1000ml, regulate pH (caustic lye of soda) to 7.5 with 8%, medicinal liquid filters 40 bottles of fills, Zha Gai with the microporous filter membrane of 0.45um, 0.22um, in 110 ℃ of pressure sterilizings 40 minutes, promptly.
Embodiment 5:
Troxerutin 200mg breviscapine 10mg
Get troxerutin 2g, breviscapine 0.10g and add injection water 200ml, regulate pH value with 8% sodium hydroxide solution and make its dissolving.Sodium chloride 3.04g, sodium citrate 0.6g are mixed with 10% solution, adding 0.2% active carbon boiled 15 minutes, filter, filtrate adds anhydrous sodium sulfite, EDTA-2Na, troxerutin and breviscapine solution, regulating pH (caustic lye of soda with 8%) is 7.5, and add 0.15% active carbon and boiled 15 minutes, add dimension C dissolving, filter, filtrate adds the injection water to 1000ml, regulate pH (caustic lye of soda) to 7.5 with 8%, medicinal liquid filters 40 bottles of fills, Zha Gai with the microporous filter membrane of 0.45um, 0.22um, in 110 ℃ of pressure sterilizings 40 minutes, promptly.
Embodiment 6:
Troxerutin 200mg breviscapine 20mg
Get troxerutin 2g, breviscapine 0.20g and add injection water 200ml, regulate pH value with 8% sodium hydroxide solution and make its dissolving.Sodium chloride 3.04g, sodium citrate 0.6g are mixed with 10% solution, adding 0.2% active carbon boiled 15 minutes, filter, filtrate adds anhydrous sodium sulfite, EDTA-2Na, troxerutin and breviscapine solution, regulating pH (caustic lye of soda with 8%) is 7.5, and add 0.15% active carbon and boiled 15 minutes, add dimension C dissolving, filter, filtrate adds the injection water to 1000ml, regulate pH (caustic lye of soda) to 7.5 with 8%, medicinal liquid filters 40 bottles of fills, Zha Gai with the microporous filter membrane of 0.45um, 0.22um, in 110 ℃ of pressure sterilizings 40 minutes, promptly.
Embodiment 7:
Method according to embodiment 1～6 adds the starch of inventory 10% and 3% magnesium stearate together with troxerutin and breviscapine, and mixing is granulated, drying, and tabletting promptly gets Tabules of the present invention.
Embodiment 8:
Troxerutin and breviscapine are added together the adjuvants such as antiseptic, stabilizing agent of sucrose water and convention amount according to the method for embodiment 1～6, filter, sterilization, divide in the 10ml bottle of packing into, promptly get oral liquid formulation of the present invention.
Embodiment 9:
According to the method for embodiment 1～6 with troxerutin and breviscapine adding distil water dilution together after, carry out packing and sterilization, make injection dosage form of the present invention.
Embodiment 10:
Method according to embodiment 1～6 is diluted troxerutin and breviscapine together with water for injection, diluent filter paper sucking filtration, and filtrate is again through G
6Hang down and melt the funnel filtration, filtrate is filtered refining once more with 0.22 μ m microporous filter membrane by ultrafiltration, packing, and lyophilizing promptly gets freeze-dried powder injection dosage form of the present invention.
Claims (14)
1. pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease is characterized in that wherein containing troxerutin and breviscapine and both pharmaceutically acceptable excipient of effective dose.
2. pharmaceutical composition according to claim 1 is characterized in that troxerutin intermediate content is 50-96%.
3. pharmaceutical composition according to claim 1 is characterized in that breviscapine intermediate content is 50-96%.
4. according to the described pharmaceutical composition of claim 1-3, it comprises: 10-1000 weight portion troxerutin, 2-100 weight portion breviscapine.
5. any one pharmaceutical composition according to claim 4, it comprises: 50-600 weight portion troxerutin, 5-50 weight portion breviscapine.
6. any one pharmaceutical composition according to claim 4, it comprises: 80-120 weight portion troxerutin, 10-40 weight portion breviscapine.
7. any one pharmaceutical composition according to claim 4, it comprises: 100 weight portion troxerutins, 20 weight portion breviscapines.
8. according to the described pharmaceutical composition of claim 4-7, it is characterized in that its dosage form comprises injection, capsule, tablet, granule, oral liquid.
9. drug combination injection according to claim 8 (little pin, powder pin, glucose infusion liquid and sodium chloride transfusion), it is characterized in that containing in the medicinal liquid Radix Scutellariae extract and Caulis Fibraureae extract, and be equipped with pharmaceutic adjuvant, adjuvant comprises diluent, osmotic pressure regulator, excipient, wherein contains effective ingredient troxerutin 80-120mg/ bottle and breviscapine 10-40mg/ bottle.
10. drug combination injection according to claim 9 (little pin, powder pin, glucose infusion liquid and sodium chloride transfusion) wherein contains effective ingredient troxerutin 100mg/ bottle and breviscapine 20mg/ bottle.
11. pharmaceutical composition according to claim 8 is characterized in that: every or every contains effective ingredient troxerutin 50-600mg and breviscapine 5-50mg.
12. pharmaceutical composition according to claim 11 is characterized in that: every or every contains effective ingredient troxerutin 80-120mg and breviscapine 10-40mg.
13. pharmaceutical composition according to claim 11 is characterized in that: every or every contains effective ingredient troxerutin 100mg and breviscapine 20mg.
14., it is characterized in that this method is according to the described preparation of drug combination method of claim 1-10:
Get troxerutin 1g, breviscapine 0.20g and add injection water 200ml, regulate pH value with 8% sodium hydroxide solution and make its dissolving.Sodium chloride 3.04g, sodium citrate 0.6g are mixed with 10% solution, adding 0.2% active carbon boiled 15 minutes, filter, filtrate adds anhydrous sodium sulfite, EDTA-2Na, troxerutin and breviscapine solution, regulating pH (caustic lye of soda with 8%) is 7.5, and add 0.15% active carbon and boiled 15 minutes, add dimension C dissolving, filter, filtrate adds the injection water to 1000ml, regulate pH (caustic lye of soda) to 7.5 with 8%, medicinal liquid filters 40 bottles of fills, Zha Gai with the microporous filter membrane of 0.45um, 0.22um, in 110 ℃ of pressure sterilizings 40 minutes, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100788124A CN100522179C (en) | 2004-09-06 | 2004-09-06 | Medicine composition for treating cardiovascular and cerebrovascular disease and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100788124A CN100522179C (en) | 2004-09-06 | 2004-09-06 | Medicine composition for treating cardiovascular and cerebrovascular disease and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1729989A true CN1729989A (en) | 2006-02-08 |
| CN100522179C CN100522179C (en) | 2009-08-05 |
Family
ID=35962435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100788124A Expired - Fee Related CN100522179C (en) | 2004-09-06 | 2004-09-06 | Medicine composition for treating cardiovascular and cerebrovascular disease and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100522179C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110339172A (en) * | 2019-07-02 | 2019-10-18 | 湖北美林药业有限公司 | Troxerutin for Injection and preparation method thereof |
| CN112057424A (en) * | 2020-09-18 | 2020-12-11 | 开封康诺药业有限公司 | Troxerutin freeze-dried powder injection and preparation method thereof |
-
2004
- 2004-09-06 CN CNB2004100788124A patent/CN100522179C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110339172A (en) * | 2019-07-02 | 2019-10-18 | 湖北美林药业有限公司 | Troxerutin for Injection and preparation method thereof |
| CN110339172B (en) * | 2019-07-02 | 2021-12-03 | 湖北美林药业有限公司 | Troxerutin for injection and preparation method thereof |
| CN112057424A (en) * | 2020-09-18 | 2020-12-11 | 开封康诺药业有限公司 | Troxerutin freeze-dried powder injection and preparation method thereof |
| CN112057424B (en) * | 2020-09-18 | 2022-09-16 | 开封康诺药业有限公司 | Troxerutin freeze-dried powder injection and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100522179C (en) | 2009-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2469490T3 (en) | Composition comprising Salvia miltiorrhiza, Ginseng, Borneol, for the treatment of heart and cerebrovascular diseases | |
| CN1923227A (en) | Traditional Chinese medicinal formulation for treating ischemic cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN1112198C (en) | Thrombolytic medicine and its preparation and use | |
| CN101199560B (en) | Ginkgo leaf extract and preparing method thereof | |
| CN100522179C (en) | Medicine composition for treating cardiovascular and cerebrovascular disease and its preparation method | |
| CN103083370B (en) | Novel application of total flavones of hippophae rhamnoides | |
| CN1272026C (en) | Medicinal composition for treating cardiocerebral vasculr disease and its preparing method | |
| CN1919206A (en) | Vitexin injection and oral administration preparation thereof | |
| CN1785248B (en) | Effervescent of compounding medicines | |
| CN107998117B (en) | A kind of combination of oral medication for treating capillary leak syndrome | |
| CN101081220A (en) | Angiocardiopathy treating traditional Chinese medicine and the preparing technology thereof | |
| CN102973544B (en) | Salvianolic acid A lyophilized powder and application thereof in preparing medicaments | |
| CN102988307B (en) | A kind of salvianolic acid A freeze-dried powder and prepare medicinal usage | |
| CN1425412A (en) | Compound oral thrombolytic preparation and its preparing method | |
| CN1954828A (en) | Medical composite for treating cardio-cerebral vascular disease and its preparation method and application | |
| CN1868500A (en) | Medicine composition contg. tetramethylpyrazine, prepn. method and use thereof | |
| CN1778302A (en) | 2-glucoside Chinese medicinal oral preparation and its making method thereof | |
| CN1915269A (en) | Medicinal composition, preparation method and quality control method | |
| CN1915293A (en) | Medicinal composition, preparation method and quality control method | |
| CN1969912A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1915295A (en) | Medicinal composition, preparation method and quality control method | |
| CN1915294A (en) | Medicinal composition, preparation method and quality control method | |
| CN1965921A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1969949A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1965920A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090805 Termination date: 20100906 |